Schneider and Kovelowski (1990) showed that chronic low-dose N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to monkeys caused cognitive dysfunction without significant motor impairment on tasks thought to be related to the caudate-frontal axis. The cognitive difficulties were similar to those seen in monkeys with frontal lesions, normal young monkeys, and normal young children. The caudate-frontal dysfunction is consistent with the cognitive difficulties that are thought to exist in children with attention deficit disorder (ADD). The caudate-frontal dysfunction is also consistent with the distribution of decreased cerebral blood flow and, presumably, decreased metabolism that has recently been found in children with ADD. In monkeys given chronic low-dose MPTP, pilot neurochemical studies have suggested abnormalities in dopamine and norepinephrine metabolism, the two neurotransmitters most frequently linked with ADD. We suggest that chronic low-dose MPTP induced cognitive dysfunction in primates may not only be a model for the cognitive disturbances that accompany Parkinson's disease but may also aid in understanding the cognitive dysfunction seen in children with ADD. (J Child Neurol 1991;6(Suppl):S80-S87).
Get full access to this article
View all access options for this article.
References
1.
Mesulam MM: Principles of Behavioral Neurology. Philadelphia , FA Davis, 1985, p 29.
2.
Voeller KKS , Alexander AW, Carter RL, Heilman KM: Motor impersistence in children with attention deficit hyperactivity disorder: decreases in response to treatment with methylphenidate . Neurology1989;39(Suppl 1):276.
3.
Voeller KKS , Heilman KM: Attention deficit disorder in children: a neglect syndrome? Neurology1988;38:806-808.
4.
Johnston CW: The neuropsychological evaluation of attention deficit disorder. Psychiatr Ann1986;16:47-51.
5.
Shaywitz BA, Cohen DJ, Bowers MB: CSF monoamine metabolites in children with minimal brain dysfunction: Evidence for alteration of brain dopamine. J Pediatr1977;90:67-71.
6.
Shaywitz BA, Yager RD, Klopper JH: Selective brain dopamine depletion in developing rats: An experimental model of minimal brain dysfunction. Science1976 ;191:305-308.
7.
Zametkin AJ, Rapoport JL: Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? J Am Acad Child Adolesc Psychiatry1987;26:676-686.
8.
Garfinkel B. , Wender PH, Sloman L., et al: Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry1983;22:343-348.
9.
Kennard MA, Spencer S., Fountan G.: Hyperactivity in monkeys following lesions of the frontal lobes. J Neurophysiol1941;4:512-524.
10.
Pontius AA: Dysfunction patterns analogous to frontal lobe system and caudate nucleus syndromes in some groups of minimal brain dysfunction. J Am Med Wom Assoc1973; 28:285-292.
11.
Mattes JA: The role of frontal lobe dysfunction in childhood hyperkinesis. Compr Psychiatry1980;21:358-369.
12.
Njioktzien C. : Pediatric Behavioral Neurology. Amsterdam, Suyi Publicaties, 1988 , p 231.
13.
Lou HC, Henriksen L., Bruhn P.: Focal cerebral byperperfusion in children with dysphasia and/or attention deficit disorder. Arch Neurol1984;41:825-829.
14.
Schneider JS : Basal ganglia role in behavior. Importance of sensory gating and its relevance in psychiatry. Biol Psychiatry1984;19:1693-1710.
15.
Lidsky TI, Manetto C., Schneider JS: A consideration of sensory factors involved in motor functions of the basal ganglia. Brain Res Rev1985;9:133-146.
16.
Schneider JS : Ingestion related neuronal activity in caudate and entopenduncular nuclei in the cat. Exp Neurol1987; 95:216-223.
17.
Pontius AA: Dysfunction patterns analogous to frontal lobe system and caudate nucleus syndromes in some groups of minimal brain dysfunction. J Am Med Women Assoc1973; 28:285-292.
18.
Wender PH: Minimal Brain Dysfunction in Children. New York , Wiley-Interscience, 1971.
19.
Lou HC, Henriksen L., Bruhn P., et al: Striatal dysfunction in attention deficit disorder. Arch Neurol1989;465:48-52.
20.
Roeltgen MG , Roeltgen DP, Heilman KM: Unilateral motor impersistence and hemispatial neglect from a right striatal lesion. Neuropsychol Neuropsychiatry Behav Neurol1989;2:125-135.
21.
Ballard PA, Teturd JW, Longston JW: Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology1985;35:949-956.
22.
Stern Y., Langston JW: Intellectual changes in patients with MPTP-induced parkinsonism. Neurology1985;35:1506-1509.
23.
Schneider JS , Kovelowski CJ: Chronic exposure to low doses of MPTP 1. Cognitive deficits in motor asymptomatic monkeys. Brain Res1990;519:122-128.
24.
Freedman M. , Oscar-Berman M.: Selective delayed response deficits in Parkinson's and Alzheimer's disease. Arch Neurol1986;43:886-890.
25.
Diamond A., Goldman-Rakic PS: Evidence for involvement in prefrontal cortex in cognitive changes during the first year of life: Comparison of performance of human infant and rhesus monkeys on a detour task with transparent barrier. Neurosci Abstr (Part II) 1985;11:832.
26.
Rolls ET, Williams GV: Sensory and movement-related neuronal activity in different regions of the primate striatum, in Schneider JS, Lidsky TI (eds): Basal Ganglia and Behavior Sensory Aspects of Motor Functioning. Toronto, Hans Huber, pp 37-60.
27.
Schneider JS , Unquez G., Yuwiler A., et al: Deficits in operant behavior in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain1988;111:1265-1285.
28.
Diamond A.: Developmental time course in human infants and infant monkeys, and the neural bases of inhibitory control in reaching. Presented at The Development and Neural Bases of Higher Cognitive Functions , Philadelphia, PA, May, 1989.
29.
Schneider JS : Chronic exposure to low doses of MPTP II. Neurochemical and pathological consequences in monkeys. Brain Res, in press.
30.
Davis GD: Effects of control, excitant and depressant drugs on locomotor activity in the monkeys. Am J Physiol1958;188:619-623.
31.
Miller FE, Heffner TG, Kotake C., et al: Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of dopamine depletion. Brain Res1981;229:123-132.
32.
Chelyne GJ, Ferguson W., Koon R., et al: Frontal lobe disinhibition in attention deficit disorder. Child Psychiatry Hum Dev1986;16:221-234.
33.
Battig K., Rosvold HE, Mishkin M.: Comparison of the effects of frontal and caudate lesions in delayed response and alternation in monkeys. J Comp Psychol1960;53:400-404.
34.
Diamond A.: Abilities and neurol mechanisms underlying AB performance. Child Dev1988;59:523-527.
35.
Diamond A., Doar B.: The performance of human infants on a measure of frontal cortex function, the delayed response task. Dev Psychobiol1989;22:271-294.
36.
Roeltgen DP , Schneider JS: Hemispatial neglect in hemiparkinsonian monkeys . Ann Neurol1989;26:126.
37.
Joyce JN, Marshall JF, Bankiewicz K., et al: Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of MPTP is associated with regional ipsilateral changes in striatal dopamine D2 receptor density. Brain Res1985;382:360-364.
38.
Cortes R., Gueye B., Pazos A., et al: Dopamine receptors in the human brain: Autoradiographic distribution of D1 sites. Neuroscience1989;28:263-273.
39.
Camps M., Cortes R., Gueye B., et al: Dopamine receptors in the human brain: Autoradiographic distribution of D2 sites. Neuroscience1989;28:275-290.
40.
Creese I., Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science1976;192:481-483.
41.
Creese I.: New insights into the regulation of dopamine receptor subtypes and their roles in behavior, in Hefti F, Weiner WJ (eds): Progress in Parkinson Research. New York, Plenum, pp 45-52.
